These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15936322)

  • 1. Role of hs-CRP measurements in the current cardiovascular risk assessment.
    Levinson SS; Elin RJ
    Clin Chim Acta; 2005 Jun; 356(1-2):225-6. PubMed ID: 15936322
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of hs-CRP measurements in the current cardiovascular risk assessment.
    García-Moll X; Ordóñez-Llanos J
    Clin Chim Acta; 2005 May; 355(1-2):215-8. PubMed ID: 15820499
    [No Abstract]   [Full Text] [Related]  

  • 3. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
    Mora S; Rifai N; Buring JE; Ridker PM
    Circulation; 2006 Aug; 114(5):381-7. PubMed ID: 16864722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [C-reactive protein in cardiovascular risk evaluation].
    Fabijanić D; Banić M; Kardum D
    Lijec Vjesn; 2006; 128(5-6):167-74. PubMed ID: 16910418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein: a new risk assessment tool for cardiovascular disease.
    Clearfield MB
    J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
    Honda H; Qureshi AR; Heimbürger O; Barany P; Wang K; Pecoits-Filho R; Stenvinkel P; Lindholm B
    Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk assessment and homocysteine and leptin levels in peritoneal dialysis and hemodialysis patients.
    Bekpinar S; Unlüçerçi Y; Genç S; Türkmen A
    Adv Perit Dial; 2005; 21():80-4. PubMed ID: 16686291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alanine aminotransferase and high sensitivity C-reactive protein: correlates of cardiovascular risk factors in youth.
    Oliveira AC; Oliveira AM; Almeida MS; Silva AM; Adan L; Ladeia AM
    J Pediatr; 2008 Mar; 152(3):337-42. PubMed ID: 18280837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein testing comes of age. Measuring low-grade inflammation can help refine cardiovascular risk.
    Harv Heart Lett; 2009 Feb; 19(6):2. PubMed ID: 19575518
    [No Abstract]   [Full Text] [Related]  

  • 11. Inflammatory biomarkers and cardiovascular risk: association or cause and effect?
    Rao M; Jaber BL; Balakrishnan VS
    Semin Dial; 2006; 19(2):129-35. PubMed ID: 16551290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bringing clarity to CRP testing. Wider use is in the offing for this simple blood test to gauge cardiac risk.
    Harv Heart Lett; 2010 Mar; 20(7):3. PubMed ID: 20586126
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of C-reactive protein in coronary risk reduction: focus on primary prevention.
    Gotto AM
    Am J Cardiol; 2007 Mar; 99(5):718-25. PubMed ID: 17317380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
    de Ferranti SD; Rifai N
    Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum C-reactive protein as a marker for wellness assessment.
    Kao PC; Shiesh SC; Wu TJ
    Ann Clin Lab Sci; 2006; 36(2):163-9. PubMed ID: 16682512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of high-sensitivity C-reactive protein serum assay results obtained using Dade-Behring BNII nephelometer and Ortho Vitros FS 5.1 clinical analyzer in respect of CRP-related risk assessment of chronic metabolic diseases.
    Kusnierz-Cabala B; Gernand W; Zabek-Adamska A; Tokarz A; Naskalski JW
    Clin Lab; 2008; 54(9-10):341-6. PubMed ID: 19097491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
    Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
    Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
    J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis.
    Dessein PH; Norton GR; Woodiwiss AJ; Joffe BI; Solomon A
    J Rheumatol; 2007 Apr; 34(4):681-8. PubMed ID: 17299845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of biomarkers for risk stratification in the prevention of cardiovascular diseases].
    Sinning C; Keller T; Blankenberg S
    Dtsch Med Wochenschr; 2009 Oct; 134(40):2019-22. PubMed ID: 19777420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.